ReeNT Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $3.79M

  • Investors
  • 6

ReeNT General Information

Description

Developer of regenerative medicine designed to provide a new system for intractable diseases in the ear, nose, and throat. The company specializes in otorhinolaryngology by developing cell sheets from patients' noses that can be transplanted into the middle ear after surgery for ventilation, enabling patients to get treatments for middle ear cholesteatoma and hearing loss.

Contact Information

Website
www.reent.co.jp
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3-25-8, Nishi-Shinbashi
  • Minato-ku
  • Tokyo, 105-0003
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3-25-8, Nishi-Shinbashi
  • Minato-ku
  • Tokyo, 105-0003
  • Japan

ReeNT Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ReeNT Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 27-May-2026 $3.79M Completed Generating Revenue
5. Early Stage VC 30-Dec-2024 Completed Generating Revenue
4. Accelerator/Incubator 01-Jan-2023 Completed Generating Revenue
3. Early Stage VC (Series A) 21-Oct-2022 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
1. University Spin-Out 27-Aug-2021 Completed Generating Revenue
To view ReeNT’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ReeNT Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alfresa Holdings Corporation Minority
Intellectual Property Acceleration Program for Startups Accelerator/Incubator
Mitsubishi UFJ Capital Venture Capital Minority
Nissay Capital Venture Capital Minority
Kawasaki Deep Tech Accelerator Accelerator/Incubator
You’re viewing 5 of 6 investors. Get the full list »

ReeNT FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process